Bayer AG vs Target Corporation: Strategic Comparison

This in-depth comparison examines Bayer AG and Target Corporation across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Bayer AG on its own, evaluating Target Corporation, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Bayer AG and Target Corporation is widest.

On the headline numbers, Bayer AG reports annual revenue of ~$51.5B against $104.8B for Target Corporation, while their respective market capitalizations stand at $47.1B and $72.0B. Bayer AG is headquartered in Germany and Target Corporation in United States, and those different home markets shape how each company competes.

Bayer AG: Bayer is a German life-science group founded in 1863 and headquartered in Leverkusen. Crop Science is the largest division, with ~$24.4 billion (EUR 21,622 million) of 2025 sales from seeds, traits, crop protection chemicals and the Climate FieldView digital platform. Pharmaceuticals follows at ~$20.1 billion (EUR 17,829 million), built on oncology, cardiovascular and renal medicines, women's health and radiology. Consumer Health adds ~$6.56 billion (EUR 5,802 million) of over-the-counter brands including Aspirin, Aleve and Claritin. Bayer chemists created aspirin in the 1890s; the company also bought Monsanto in 2018, and the litigation that came with that deal still shapes how it is valued.

Target Corporation: Target is a retailer whose value comes from making mass retail feel curated. The business is strongest when stores, digital channels, owned brands and fulfillment services reinforce one another.

Bayer AG and Target Corporation pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Bayer AG and Target Corporation.

Bayer AG business model: Bayer runs two very different businesses plus a consumer brand portfolio. Pharmaceuticals spent ~$3.91 billion (EUR 3,456 million) on research and development in 2025 to develop and launch patented specialty medicines in oncology, cardiovascular and renal disease, women's health and radiology, and sells them to hospitals and specialist prescribers at high gross margins. Crop Science breeds hybrid seed, licenses biotech traits such as insect resistance and herbicide tolerance, and sells matching herbicides, fungicides and insecticides through dealer and distributor networks, with the Climate FieldView platform layered on top. Consumer Health sells over-the-counter brands through pharmacy, grocery and e-commerce channels. In 2025 Crop Science produced ~$24.4 billion (EUR 21,622 million) of sales, Pharmaceuticals ~$20.1 billion (EUR 17,829 million) and Consumer Health ~$6.56 billion (EUR 5,802 million).

Target Corporation business model: Target runs a general-merchandise, big-box retail model that pairs low-margin essentials (groceries, household basics) to drive store traffic with higher-margin discretionary categories (apparel, home decor, and private-label brands) to drive profit -- the classic 'basket size' strategy. Owned and exclusive brands make up a large share of sales and carry better margins than national brands, a strategy Target has leaned on more heavily to compete with Walmart's scale and Amazon's convenience. Digital and same-day fulfillment, built around the 2017 Shipt (about $550 million) and Grand Junction acquisitions, let Target use its stores as fulfillment hubs -- a model that became central to growth during the pandemic and remains core to its omnichannel strategy today. FY2025 revenue was $104.780 billion, continuing a decline from $107.412 billion in fiscal 2023, as the company worked through a sales and stock slump serious enough to trigger a CEO change; FY2026 has shown a rebound, with Q1 net sales up 6.7% and Q2 net sales up 5.3%. Non-merchandise revenue, which includes Roundel advertising, Target Circle 360 membership fees and the Target+ marketplace, grew more than 20% in Q2 FY2026, adding higher-margin income on top of merchandise sales.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Bayer AG stack up against those of Target Corporation.

Bayer AG competitive advantage: Bayer's strongest position is in seeds and traits. Corn Seed and Traits alone generated ~$8.08 billion (EUR 7,149 million) of sales in 2025, up 9.0 percent as reported, because growers buy hybrid seed together with the trait packages licensed into it and then buy matching crop protection chemistry. Changing seed supplier means changing agronomic practice mid-rotation, which slows share loss. In Pharmaceuticals the advantage is narrower and product-specific: established prescriber relationships in oncology, cardiology, nephrology and ophthalmology, and a radiology business that grew on volume in every region in 2025.

Target Corporation competitive advantage: Target's advantage is the mix of curated merchandise, owned brands, convenient stores, same-day fulfillment and a brand position between discount utility and design-led retail.

Future prospects matter as much as current results. The growth strategies below explain how Bayer AG and Target Corporation each plan to expand from here.

Bayer AG growth strategy: After a strategic review in March 2024 Bayer decided not to break itself up, keeping the three divisions together while it works on litigation and debt. Growth therefore has to come from inside: scaling Nubeqa, which reached ~$2.7 billion (EUR 2,385 million) of sales in 2025, and Kerendia at ~$937 million (EUR 829 million); launching Lynkuet, Beyonttra and Hyrnuo; filing gadoquatrane in radiology; and bringing the icafolin-methyl herbicide to market from 2028, starting in Brazil. The cost side is the Dynamic Shared Ownership model, which Bayer says has removed about 12,000 positions and roughly half of its management positions and which underpins a ~$2.26 billion (EUR 2 billion) annual savings target for 2026. The supervisory board extended Bill Anderson's contract to March 31, 2029 in July 2025.

Target Corporation growth strategy: Target is focusing on merchandising authority, guest experience, technology acceleration, team and community strength, stores-as-hubs, same-day fulfillment, retail media and owned-brand renewal.

A closer look at the financial trajectory of Bayer AG and Target Corporation rounds out the comparison.

Bayer AG: Bayer's accounts still carry the 2018 Monsanto acquisition. FY2025 sales were ~$51.5 billion (EUR 45,575 million), down 2.2 percent as reported and up 1.1 percent adjusted for currency and portfolio. EBITDA before special items was ~$11 billion (EUR 9.7 billion) and free cash flow ~$2.35 billion (EUR 2,084 million), yet the group reported an EBIT of minus ~$1.22 billion (EUR 1,077 million) and a net loss of ~$4.09 billion (EUR 3,620 million), because other operating expenses net of income reached minus ~$8.34 billion (EUR 7,377 million), mainly litigation provisions. Net financial debt fell 8.5 percent to ~$33.7 billion (EUR 29,843 million). The dividend has stayed at the legally required minimum of EUR 0.11 per share since 2023, so cash goes to debt and settlements rather than shareholders.

Target Corporation: Target's revenue fell three years in a row, from $109.1 billion in fiscal 2022 to $104.8 billion in fiscal 2025, while FY2025 net income was $3.705 billion. Fiscal 2026 has reversed the trend so far. Q2 FY2026 net sales rose 5.3% to $26.5 billion, comparable sales grew 3.8% on a 3.6% traffic gain, and digital comparable sales rose 8.7% with same-day delivery up more than 25%. Q2 GAAP EPS was $4.11 versus $2.05 a year earlier, but $1.65 of that came from $994 million of pretax tariff refunds; excluding refunds, EPS grew about 20%. Management now guides to roughly 5% net sales growth for fiscal 2026 and EPS of $9.90 to $10.90.